- Synthesis, inhibition properties against xanthine oxidase and molecular docking studies of dimethyl N-benzyl-1H-1,2,3-triazole-4,5-dicarboxylate and (N-benzyl-1H-1,2,3-triazole-4,5-diyl)dimethanol derivatives
-
This study focused on synthesis various dimethyl N-benzyl-1H-1,2,3-triazole-4,5-dicarboxylate and (N-benzyl-1H-1,2,3-triazole-4,5-diyl)dimethanol derivatives under the conditions of green chemistry without the use of solvent and catalysts. Their inhibition properties were also investigated on xanthine oxidase (XO) activity. All dimethanol and dicarboxylate derivatives exhibited significant inhibition activities with IC50 values ranging from 0.71 to 2.25 μM. Especially, (1-(3-bromobenzyl)-1H-1,2,3-triazole-4,5-diyl)dimethanol (5c) and dimethyl 1-(4-chlorobenzyl)-1H-1,2,3-triazole-4,5-dicarboxylate (6 g) compounds were found to be the most promising derivatives on the XO enzyme inhibition with IC50 values 0.71 and 0.73 μM, respectively. Moreover, the double docking procedure was to evaluate compound modes of inhibition and their interactions with the protein (XO) at atomic level. Surprisingly, the docking results showed a good correlation with IC50 [correlation coefficient (R2 = 0.7455)]. Also, the docking results exhibited that the 5c, 6f and 6 g have lowest docking scores ?4.790, ?4.755, and ?4.730, respectively. These data were in agreement with the IC50 values. These results give promising beginning stages to assist in the improvement of novel and powerful inhibitor against XO.
- Yagiz, Güler,Noma, Samir Abbas Ali,Altundas, Aliye,Al-khafaji, Khattab,Taskin-Tok, Tugba,Ates, Burhan
-
-
- Cooperative interplay between a flexible PNN-Ru(II) complex and a NaBH4 additive in the efficient catalytic hydrogenation of esters
-
A catalyst loading of between 0.001-0.05 mol% of the PNN-bearing ruthenium(II) complex [fac-PNN]RuH(PPh3)(CO) (PNN = 8-(2-diphenylphosphinoethyl)amidotrihydroquinoline), in combination with 5 mol% NaBH4, efficiently catalyzes the hydrogenation of esters to their corresponding alcohols under mild pressures of hydrogen. Both aromatic and aliphatic esters can be converted with high values of TON or TOF achievable. Mechanistic investigations using both DFT calculations and labeling experiments highlight the cooperative role of NaBH4 in the catalysis while the catalytically active species has been established as trans-dihydride [mer-PNHN]RuH2(CO) (PNHN = 8-(2-diphenylphosphinoethyl)aminotrihydroquinoline). The stereo-structure of the PNHN-ruthenium species greatly affects the activity of the catalyst, and indeed the cis-dihydride isomer [fac-PNHN]RuH2(CO) is unable to catalyze the hydrogenation of esters until ligand reorganization occurs to give the trans isomer.
- Wang, Zheng,Chen, Xiangyang,Liu, Bo,Liu, Qing-Bin,Solan, Gregory A.,Yang, Xinzheng,Sun, Wen-Hua
-
p. 1297 - 1304
(2017/05/05)
-
- Zinc-Mediated Efficient and Selective Reduction of Carbonyl Compounds
-
We herein describe for the first time that an optimized combination of Zn and NH4Cl can be used for the selective reduction of aldehydes and ketones to the corresponding alcohols. The aldehyde and keto groups are selectively reduced in the presence of azide, cyano, epoxy, ester, and carbon–carbon double-bond functional groups. A broad functional-group compatibility, chemoselective reduction of aldehydes in the presence of ketones, and selective reduction of isatins at the C3 carbonyl group are the highlights of the present method.
- Mandal, Tirtha,Jana, Snehasish,Dash, Jyotirmayee
-
p. 4972 - 4983
(2017/09/13)
-
- Method for preparing alcohol through catalytic hydrogenation reduction of carboxylate
-
The invention discloses a method for preparing alcohol through catalytic hydrogenation reduction of a carboxylate compound with 2-(diphenylphosphinoethyl)-(5,6,7,8-tetrahydroquinolyl)amine as a ruthenium complex catalyst of ligand. The catalyst has high-efficiency catalysis activity on alkyl benzoate, aromatic esters and fatty esters. The preparation method is simple and has good stability, the catalysis activity of the catalyst is high, and the dosage of the catalyst is 0.025-0.005% of the mole of a substrate. The method can be used for producing alcohols, and has the advantages of simplicity, small pollution to environment, high yield and low cost. Most of carboxylate can be hydrogenated and reduced to form alcohols by using a complex represented by formula (1) with sodium borohydride as an additive, and the conversion number TOC can reach 50000; and a cocaalyst sodium borohydride is used to substitute most of alcoholic alkalis used as a catalyst in especially used in aromatic esters with electron-withdrawing substituent, so the cost is reduced, operation is simple, and industrial production is easy.
- -
-
Paragraph 0023; 0025; 0040
(2016/12/07)
-
- Synthesis of structurally diverse diarylketones through the diarylmethyl sp3 C-H oxidation
-
Under open-flask conditions, an efficient method to assemble a series of diversely functionalized diarylketones in the presence of commercially available NBS has been developed. Yields of up to 99% have been achieved employing diarylmethanes as starting material. Based on 18O-labeled experiment, the addition of stoichiometric water eventually leads to excellent yields in all carbonylation cases.
- He, Chao,Zhang, Xiaohui,Huang, Ruofeng,Pan, Jing,Li, Jiaqiang,Ling, Xuege,Xiong, Yan,Zhu, Xiangming
-
supporting information
p. 4458 - 4462
(2014/08/05)
-
- 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS
-
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
- -
-
Page/Page column 24
(2014/08/07)
-
- COMPOUNDS
-
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
- -
-
Paragraph 0149; 0150; 0151
(2014/08/07)
-